[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK in…

The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib ...

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Prog…

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of ...
Scientific Research Publishing

Intelligent Agents in Cybersecurity: Deep Learning to Analyze User Behavior Applying ()

The research aim is to develop an intelligent agent for cybersecurity systems capable of detecting abnormal user behavior ...